Abstract
A computation model has been developed for the rational design of bioactive pharmacophore sites as anti-viral candidates based on available X-ray structures of drugs. The compounds have been previously screened for anti-viral activity against HIV-Integrase (HIV IN). Amongst the series, the most potent compounds, 4k and 4d (low mu M IC50) were tested in viral cultures for their ability to present potentials (O (1) (delta-) -O (2) (delta-) -O (3) (delta-) ) for anti-viral pharmacophore site but represent a potential risk of toxicity. Furthermore, the compounds 4k and 4d showed potent anti-HIV IN activity. A good correlation was obtained between the theoretical predictions of bioavailability using POM suite (Petra/Osiris/Molinspiration containing Lipinski's rule-of-five) and experimental verification. The structure-activity relationships were also analyzed to vindicate the POM results.
A series of known anti-HIV agents; the amide-containing diketoacids were POM and 3D-QSAR analyzed in goal to understand and develop more potent/selective HIV IN inhibitors. Their inhibition of HIV IN was attributed to them containing O-1,O-2,O-4-pharmacophore site. The structure-activity relationships were discussed on the basis of POM analyses.